These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

133 related articles for article (PubMed ID: 35713564)

  • 21. A double blind, randomized, active controlled study to assess the safety, tolerability and immunogenicity of measles, mumps rubella, and varicella vaccine (MMRV) manufactured using an alternative process.
    Marshall GS; Senders SD; Shepard J; Twiggs JD; Gardner J; Hille D; Hartzel J; Valenzuela R; Stek JE; Helmond FA
    Hum Vaccin Immunother; 2016 Aug; 12(8):2188-2196. PubMed ID: 27149048
    [TBL] [Abstract][Full Text] [Related]  

  • 22. A combined measles, mumps, rubella and varicella vaccine (Priorix-Tetra): immunogenicity and safety profile.
    Czajka H; Schuster V; Zepp F; Esposito S; Douha M; Willems P
    Vaccine; 2009 Nov; 27(47):6504-11. PubMed ID: 19665608
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Combination measles, mumps, rubella and varicella vaccine.
    Arbeter AM; Baker L; Starr SE; Levine BL; Books E; Plotkin SA
    Pediatrics; 1986 Oct; 78(4 Pt 2):742-7. PubMed ID: 3763291
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The safety and immunogenicity of a quadrivalent measles, mumps, rubella and varicella vaccine in healthy children: a study of manufacturing consistency and persistence of antibody.
    Lieberman JM; Williams WR; Miller JM; Black S; Shinefield H; Henderson F; Marchant CD; Werzberger A; Halperin S; Hartzel J; Klopfer S; Schödel F; Kuter BJ;
    Pediatr Infect Dis J; 2006 Jul; 25(7):615-22. PubMed ID: 16804432
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Cost-effectiveness of routine varicella vaccination using the measles, mumps, rubella and varicella vaccine in France: an economic analysis based on a dynamic transmission model for varicella and herpes zoster.
    Littlewood KJ; Ouwens MJ; Sauboin C; Tehard B; Alain S; Denis F
    Clin Ther; 2015 Apr; 37(4):830-841.e7. PubMed ID: 25721380
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Varicella vaccine dose depended effectiveness and waning among preschool children in Hong Kong.
    Chan YD; Edmunds WJ; Chan HL; Wong ML; Au KA; Chuang SK; van Hoek AJ; Flasche S
    Hum Vaccin Immunother; 2020 Mar; 16(3):499-505. PubMed ID: 31642729
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Safety and immunogenicity of concurrent administration of measles-mumps-rubella-varicella vaccine and PedvaxHIB vaccines in healthy children twelve to eighteen months old. The MMRV Study Group.
    Reuman PD; Sawyer MH; Kuter BJ; Matthews H
    Pediatr Infect Dis J; 1997 Jul; 16(7):662-7. PubMed ID: 9239770
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Immunogenicity and safety of two tetravalent (measles, mumps, rubella, varicella) vaccines coadministered with hepatitis a and pneumococcal conjugate vaccines to children twelve to fourteen months of age.
    Blatter MM; Klein NP; Shepard JS; Leonardi M; Shapiro S; Schear M; Mufson MA; Martin JM; Varman M; Grogg S; London A; Cambron P; Douha M; Nicholson O; da Costa C; Innis BL
    Pediatr Infect Dis J; 2012 Aug; 31(8):e133-40. PubMed ID: 22622699
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Evaluation of a quadrivalent measles, mumps, rubella and varicella vaccine in healthy children.
    Shinefield H; Black S; Digilio L; Reisinger K; Blatter M; Gress JO; Brown ML; Eves KA; Klopfer SO; Schödel F; Kuter BJ
    Pediatr Infect Dis J; 2005 Aug; 24(8):665-9. PubMed ID: 16094217
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The impact of 2-dose routine measles, mumps, rubella, and varicella vaccination in France on the epidemiology of varicella and zoster using a dynamic model with an empirical contact matrix.
    Ouwens MJ; Littlewood KJ; Sauboin C; Téhard B; Denis F; Boëlle PY; Alain S
    Clin Ther; 2015 Apr; 37(4):816-829.e10. PubMed ID: 25726457
    [TBL] [Abstract][Full Text] [Related]  

  • 31. A new challenge for Europe: introducing a pediatric quadrivalent vaccine for measles, mumps, rubella, and varicella.
    Ramet J
    Int J Infect Dis; 2007 Nov; 11 Suppl 2():S49-55. PubMed ID: 18162247
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Varicella vaccines and measles, mumps, rubella, and varicella vaccine.
    Bricks LF; Sato HK; Oselka GW
    J Pediatr (Rio J); 2006 Jul; 82(3 Suppl):S101-8. PubMed ID: 16826308
    [TBL] [Abstract][Full Text] [Related]  

  • 33. A new combination vaccine for measles, mumps, rubella and varicella.
    Zareba G
    Drugs Today (Barc); 2006 May; 42(5):321-9. PubMed ID: 16801995
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Clinical efficacy and effectiveness of alternative varicella vaccination strategies: An overview of reviews.
    Ahern S; Walsh KA; Paone S; Browne J; Carrigan M; Harrington P; Murphy A; Teljeur C; Ryan M
    Rev Med Virol; 2023 Jan; 33(1):e2407. PubMed ID: 36378552
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Immunogenicity and safety of a second dose of measles-mumps-rubella-varicella vaccine in healthy children aged 5 to 6 years.
    Vesikari T; Baer M; Willems P
    Pediatr Infect Dis J; 2007 Feb; 26(2):153-8. PubMed ID: 17259879
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Immunogenicity and safety of intramuscular versus subcutaneous administration of a combined measles, mumps, rubella, and varicella vaccine to children 12 to 18 months of age.
    Haas H; Richard P; Eymin C; Fiquet A; Kuter B; Soubeyrand B
    Hum Vaccin Immunother; 2019; 15(4):778-785. PubMed ID: 30481110
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Long-term immunogenicity of measles, mumps and rubella-containing vaccines in healthy young children: A 10-year follow-up.
    Carryn S; Feyssaguet M; Povey M; Di Paolo E
    Vaccine; 2019 Aug; 37(36):5323-5331. PubMed ID: 31345639
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The immunogenicity and safety of a tetravalent measles-mumps-rubella-varicella vaccine when co-administered with conjugated meningococcal C vaccine to healthy children: A phase IIIb, randomized, multi-center study in Italy.
    Durando P; Esposito S; Bona G; Cuccia M; Desole MG; Ferrera G; Gabutti G; Pellegrino A; Salvini F; Henry O; Povey M; Marchetti F
    Vaccine; 2016 Aug; 34(36):4278-84. PubMed ID: 27423382
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Sixteen years of global experience with the first refrigerator-stable varicella vaccine (Varilrix).
    Kreth HW; Lee BW; Kosuwon P; Salazar J; Gloriani-Barzaga N; Bock HL; Meurice F
    BioDrugs; 2008; 22(6):387-402. PubMed ID: 18998756
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The Long-Term Clinical and Economic Impact of Universal Varicella Vaccination in Slovenia.
    Burgess C; Kujawski S; Lapornik A; Bencina G; Pawaskar M
    J Health Econ Outcomes Res; 2022; 9(2):95-102. PubMed ID: 36196453
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.